AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
AMN

AMN Healthcare Services Inc (AMN) fair value

Healthcare · Medical Care Facilities · NYSE · United States
$48.01+2.54%
Market cap $1.9BNext earnings 2026-11-05Updated Oct 17, 2026
Add earnings to calendarGoogle
Our verdict
Trades 33% below our fair value
Price
$48.01
Model fair valueConfidence: good
$71.27
Model range
$64.86 to $78.75
Fair value $71.27
Price $48.01
2 models fit AMN Healthcare Services Inc and they agree: 2 of 2 land within 15% of the average. The price is below every model.
Two or more of our models back this value.
Large discount(i)Silver66
Valued as a mature, profitable company: Discounted cash flow, P/E comparison, EV/EBITDA comparison, and Dividend discount.
ACCE opinionAMN Healthcare Services Inc (AMN)
Fair value (2 models)
$71.27
ACCE price target
$59.00
Rating
Undervalued
Horizon
12 months
Fair value published on 18 Oct 2026, 00:00 CEST; previously $69.58 since 9 Oct 2026, 00:00 CEST.
ACCE price target published on 23 Oct 2026, 01:53 CEST; previously $37.00 since 12 Oct 2026, 00:00 CEST.
Price used: $48.01 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow, Dividend discount, EV/EBITDA comparison, and P/E comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
32.6% below
+48.4% to fair value
ACCE score
73
out of 100
Analysts
33% buy
9 covering
P/E
17.9x
forward 51.1x
1-year return
+140.5%
Dividend yield
0.00%

AMN Healthcare Services Inc in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

AMN Healthcare is a staffing company that places travel nurses, allied health professionals and physicians into hospitals and health systems, and it also runs a language services and workforce solutions business. The attraction is that demand for clinical labor stays structurally tight, and AMN's scale in travel nursing gives it a sourcing and recruiting footprint that smaller agencies struggle to match. The business is cyclical rather than growing, though: revenue growth is only 2.3%, and the operating margin of 4.0% shows how thin the spread is between staffing revenue and what it costs to deliver it. At 14.9 times trailing earnings and 18.0 times forward, the market is not paying a premium for a recovery that has not yet shown up in the top line. The question for a deeper look is whether a 15.6% return on equity and a 27.8% gross margin can hold as hospital staffing normalizes after the pandemic-era surge, and whether margin expansion follows if volumes stabilize.

AI-assisted·How I use AIWritten Oct 18, 2026
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
  • moderate
    Revenue growth slowing
    Revenue grew just 2.3% year on year against a 5-year CAGR of 2.7%, so top-line momentum is thin. Earnings growth of 321.3% is off a depressed base and should not be read as underlying strength.
  • moderate
    High short interest
    Short interest stands at 11.0% of float, a meaningful bet against the shares that could amplify moves in either direction. Insider ownership is only 1.0%, so insiders are not signalling conviction.
  • moderate
    Leverage elevated
    Debt to equity is 1.25 with a thin 3.1% net margin, so earnings have little room to absorb a downturn in staffing demand.

AI research notes

AI-assisted·How I use AIWritten Oct 21, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
  • Free cash flow over the last 12 months reached $234M, a yield of 14.9% at the current price.
  • The latest quarter beat expectations, with earnings per share of 0.77 against 0.22 expected.
  • At 15.1x trailing earnings and 18.0x forward earnings, the stock trades below the sector median forward multiple of 23.9x.
Why it could disappoint
  • Return on invested capital is -5.4%, meaning the business currently earns less than its cost of capital.
  • Debt equals 1.25 times equity, a heavy load for a company with a 3.1% net margin.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.

Next results

Nov 5, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where AMN's valuation models land
Price
$48.01
Model fair value
$71.27
Model range
$64.86 to $78.75
Fair value $71.27
Price $48.01
The price is below the whole model range.
Model
Fair value
Upside
Discounted cash flow
Dividend discount
EV/EBITDA comparison
P/E comparison
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

Bearish33% buy · 9 covering analysts
● Strong buy 2● Buy 1● Hold 5● Sell 1● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Press releases mentioning this company

Recent performance

1 week
+18.6%
1 month
+41.6%
3 months
+46.0%
6 months
+135.9%
YTD
+204.6%
1 year
+140.5%

SEC filings

Recommendation history, last 12 months

DateTypeNewPreviousPrice
23 Oct 2026, 01:53 CESTACCE price target$59.00$37.00$46.82
18 Oct 2026, 00:00 CESTFair value$71.27$69.58$40.49
12 Oct 2026, 00:00 CESTACCE price target$37.00first publication$36.52
9 Oct 2026, 00:00 CESTFair value$69.58$67.90$36.53
29 Sept 2026, 00:00 CESTFair value$67.90$69.49$34.56
21 Sept 2026, 00:00 CESTFair value$69.49$71.92$34.26
18 Sept 2026, 00:00 CESTFair value$71.92$70.86$34.92
15 Sept 2026, 00:00 CESTFair value$70.86$72.58$33.34
2 Sept 2026, 00:00 CESTFair value$72.58$73.40$34.28
25 Aug 2026, 00:00 CESTFair value$73.40$72.17$34.84

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full AMN page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth55Value86Quality52Momentum97Total73
Valuation
Trailing P/E
17.9x
Forward P/E
51.1x
PEG
0.05
P/B
1.77x
EV / Revenue
0.5x
Book value/sh
$19.15
Enterprise value
$1.7B
Profitability
ROE
15.6%
FCF yield
14.04%
ROIC
-5.4%
Health and risk
Debt / equity
1.25
Dividend yield
0.00%
Beta
0.40

Price

+126.8% · 1Y

Ask anything about AMN

Answered from AMN Healthcare Services Inc fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 80% of peers
low 16.9x17.9xhigh 44.7x
ROEbetter than 83% of peers
low 2%16%high 19%
Div yieldbetter than 67% of peers
low 0.0%0.0%high 4.5%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
AMN AMN Healthcare Services Inc$48.01$7133% below17.9x15.6%5273
ASTH Astrana Health Inc. Common Stock$38.01--44.7x6.9%3572
ARDT Ardent Health Inc. Common Stock$12.36$1625% below22.7x10.0%4753
SGRY Surgery Partners Inc. Common Stock$15.90$1053% above-2.3%3343
ATT.ST Attendo AB (publ)kr 114.60kr 13515% below16.9x18.7%5263
SIA.TO Sienna Senior Living Inc.C$20.55C$1186% above38.7x6.7%4250
ADUS Addus HomeCare Corporation Common Stock$122.67$1139% above21.3x9.7%6366

Sector report card

Where AMN ranks against its sector peers on each metric.

Computing percentiles…
  • GlobeNewswire•Oct 7, 2026
    Dassault Aviation: Total number of shares and voting rights - 30 09 26
  • PR Newswire•Oct 7, 2026
    AMN Healthcare to Hold Third Quarter 2026 Earnings Conference Call on Thursday, November 5, 2026
  • PR Newswire•Oct 6, 2026
    AMN Healthcare Research Links Hospital Digital Investment to Better Patient Experience
15 more press releases · full archive on Investor+.INVESTOR
32 filings of 36
October 2026
Oct 15
Form 4Insider transactionPeriod 2026-10-15
View on SEC →
Oct 15
Form 4Insider transactionPeriod 2026-10-15
View on SEC →
September 2026
Sep 16
Form 4Insider transactionPeriod 2026-09-15
View on SEC →
29 more filings + AI summaries on Investor+.INVESTOR